Evonik stock gains as stronger earnings bolster BASF defense

Published on 11/03/2026 at 17:50 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Evonik reported stronger third-quarter earnings and expects 2026 adjusted EBITDA in the upper half of its existing range. The outlook supports the company's defense against BASF.

Evonik strengthens earnings outlook

Evonik reported a sharp third-quarter improvement despite weak economic growth and geopolitical tensions.
Cost measures and portfolio transactions remain central to the company's next steps.
Advanced Technologies led the operating recovery, while restructuring provisions kept net income negative.

Evonik, DE000EVNK013, Illustration mit AI erstellt.

Evonik reported a stronger third quarter on Tuesday, November 3, 2026, with management becoming more confident about full-year profitability. In its third-quarter press release, the specialty chemicals group said adjusted EBITDA rose 40 percent year on year to 629 million euros and that 2026 earnings are likely to land in the upper half of the 2.0 billion to 2.2 billion euro range.

What has changed since our last report

The results add a new earnings driver to the recent takeover debate with BASF. Evonik also expects fourth-quarter earnings to exceed the prior-year period, although the company continues to operate against weak economic growth and geopolitical tensions.

Sales increased 13 percent from the prior-year quarter, supported by a 10 percent rise in prices and a 2 percent increase in volumes. Free cash flow reached 369 million euros in the quarter, while first-nine-month free cash flow more than doubled to 601 million euros.

Costs remain a key investor focus

Evonik booked 313 million euros in third-quarter provisions for its extended Evonik Tailor Made efficiency program, weighing on net income. Net income was negative at 53 million euros, compared with a loss of 106 million euros in the year-earlier quarter. The company expects the program to continue through 2029.

The portfolio agenda is also advancing. Evonik said the sale process for Oxeno is progressing as planned, with a buyer expected in the coming months, while preparations for a possible sale of Syneqt have started. Advanced Technologies was the strongest operating segment, with adjusted EBITDA up 87 percent to 377 million euros.

Evonik stock traded at 21.03 euros on Lang & Schwarz at 17:42 CET on Tuesday, November 3, 2026, 0.05 percent above the Xetra close of Tuesday, November 3, 2026. The real-time quote of Evonik stock offers the latest trading reference.